Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct 1;25(R2):R123-R132.
doi: 10.1093/hmg/ddw191. Epub 2016 Jul 12.

Pathogenetics of the RASopathies

William E Tidyman  1 , Katherine A Rauen  2
Affiliations

Pathogenetics of the RASopathies

William E Tidyman et al. Hum Mol Genet. .

Abstract

The RASopathies are defined as a group of medical genetics syndromes that are caused by germ-line mutations in genes that encode components or regulators of the Ras/mitogen-activated protein kinase (MAPK) pathway. Taken together, the RASopathies represent one of the most prevalent groups of malformation syndromes affecting greater than 1 in 1,000 individuals. The Ras/MAPK pathway has been well studied in the context of cancer as it plays essential roles in growth, differentiation, cell cycle, senescence and apoptosis, all of which are also critical to normal development. The consequence of germ-line dysregulation leads to phenotypic alterations of development. RASopathies can be caused by several pathogenetic mechanisms that ultimately impact or alter the normal function and regulation of the MAPK pathway. These pathogenetic mechanisms can include functional alteration of GTPases, Ras GTPase-activating proteins, Ras guanine exchange factors, kinases, scaffolding or adaptor proteins, ubiquitin ligases, phosphatases and pathway inhibitors. Although these mechanisms are diverse, the common underlying biochemical phenotype shared by all the RASopathies is Ras/MAPK pathway activation. This results in the overlapping phenotypic features among these syndromes.

PubMed Disclaimer

Similar articles

  • RASopathies for Radiologists.
    Handa A, Tsujioka Y, Nishimura G, Nozaki T, Kono T, Jinzaki M, Harms T, Connolly SA, Sato TS, Sato Y. Handa A, et al. Radiographics. 2024 May;44(5):e230153. doi: 10.1148/rg.230153. Radiographics. 2024. PMID: 38602868
  • Molecular Genetics of Noonan Syndrome and RASopathies.
    Liao J, Mehta L. Liao J, et al. Pediatr Endocrinol Rev. 2019 May;16(Suppl 2):435-446. doi: 10.17458/per.vol16.2019.lm.molecularnoonan. Pediatr Endocrinol Rev. 2019. PMID: 31115195 Review.
  • Proceedings of the fifth international RASopathies symposium: When development and cancer intersect.
    Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F. Rauen KA, et al. Am J Med Genet A. 2018 Dec;176(12):2924-2929. doi: 10.1002/ajmg.a.40632. Epub 2018 Oct 10. Am J Med Genet A. 2018. PMID: 30302932 Free PMC article.
  • The RASopathies.
    Rauen KA. Rauen KA. Annu Rev Genomics Hum Genet. 2013;14:355-69. doi: 10.1146/annurev-genom-091212-153523. Epub 2013 Jul 15. Annu Rev Genomics Hum Genet. 2013. PMID: 23875798 Free PMC article. Review.
  • The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.
    Tidyman WE, Rauen KA. Tidyman WE, et al. Curr Opin Genet Dev. 2009 Jun;19(3):230-6. doi: 10.1016/j.gde.2009.04.001. Epub 2009 May 19. Curr Opin Genet Dev. 2009. PMID: 19467855 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rauen K.A. (2013) The RASopathies. Annu. Rev. Genomics Hum. Genet., 14, 355–369. - PMC - PubMed
    1. Yoon S., Seger R. (2006) The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors, 24, 21–44. - PubMed
    1. Aoki Y., Niihori T., Kawame H., Kurosawa K., Ohashi H., Tanaka Y., Filocamo M., Kato K., Suzuki Y., Kure S., et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat. Genet., 37, 1038–1040. - PubMed
    1. Estep A.L., Tidyman W.E., Teitell M.A., Cotter P.D., Rauen K.A. (2006) HRAS mutations in Costello syndrome: detection of constitutional activating mutations in codon 12 and 13 and loss of wild-type allele in malignancy. Am. J. Med. Genet. A, 140, 8–16. - PubMed
    1. Gibbs J.B., Sigal I.S., Poe M., Scolnick E.M. (1984) Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc. Natl. Acad. Sci. U. S. A., 81, 5704–5708. - PMC - PubMed

LinkOut - more resources

-